Premium
The significance of strong histone deacetylase 1 expression in the progression of prostate cancer
Author(s) -
Song YooHyun,
Shiota Masaki,
Tamiya Sadafumi,
Kuroiwa Kentaro,
Naito Seiji,
Tsuneyoshi Masazumi
Publication year - 2011
Publication title -
histopathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.626
H-Index - 124
eISSN - 1365-2559
pISSN - 0309-0167
DOI - 10.1111/j.1365-2559.2011.03797.x
Subject(s) - histone deacetylase , prostate cancer , cancer research , prostate , medicine , cancer , histone , oncology , biology , genetics , gene
Song Y H, Shiota M, Tamiya S, Kuroiwa K, Naito S & Tsuneyoshi M
(2011) Histopathology 58 , 773–780 The significance of strong histone deacetylase 1 expression in the progression of prostate cancerAims: Histone deacetylases (HDACs) play important roles in many types of cancer. Recently, it has been reported that HDAC1 expression in prostate cancer is significantly higher than in benign prostate cell lines and tissues. The expression of HDAC1 in association with the clinicopathological data was investigated to define its functional and pathological roles in prostate cancer. Methods and results: HDAC1 expression was examined immunohistochemically in 148 patients with prostate cancer. Strong expression of HDAC1 in benign prostate glands, high‐grade prostatic intraepithelial neoplasia (PIN) and prostate cancer was observed in 17/148 (11%), 19/71 (27%) and 69/148 (47%) patients. Strong HDAC1 expression was correlated with high Gleason score ( P = 0.025) and high pT stage ( P = 0.012). Patients with strong HDAC1 expression had higher biochemical recurrence rates ( P = 0.0010). Furthermore, strong HDAC1 expression had a significant impact on patient biochemical recurrence rates in multivariate analysis ( P = 0.004). Conclusions: These results indicate that overexpression of HDAC1 contributes to progression and poor prognosis in prostate cancer. The findings may play an important role in the emergence of effective new approaches for therapy and prognostic markers of prostate cancer.